Kennedy R. Lees
University of Glasgow
467 Papers
3.9K Citations
Kennedy R. Lees is an academic researcher from University of Glasgow. The author has contributed to research in topics: Stroke & Medicine. The author has an hindex of 86, co-authored 455 publications. Previous affiliations of Kennedy R. Lees include Ludwig Maximilian University of Munich & Cedars-Sinai Medical Center.
Chat about Author
Papers
Pneumonia and urinary tract infection after acute ischaemic stroke: a tertiary analysis of the GAIN International trial.
Stella Aslanyan,Christopher J. Weir,Christopher J. Weir,H. C. Diener,Markku Kaste,Kennedy R. Lees,Investigators +6 more
TL;DR: Pneumonia and UTI are independently associated with stroke poor outcome and patients with identified risk factors must be closely monitored for infection.
350
Glycine antagonist (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke: a randomised controlled trial
Kennedy R. Lees,Kjell Asplund,Antonio Carolei,Stephen M. Davis,Hans-Christoph Diener,Markku Kaste,Jean-Marc Orgogozo,John Whitehead +7 more
TL;DR: Treatment with gavestinel within 6 h of acute ischaemic stroke did not improve outcome, and there were no significant differences in serious side-effects between the groups.
328
Endovascular stent thrombectomy: the new standard of care for large vessel ischaemic stroke
Bruce C.V. Campbell,Geoffrey A. Donnan,Kennedy R. Lees,Werner Hacke,Pooja Khatri,Michael D. Hill,Mayank Goyal,Peter Mitchell,Jeffrey L. Saver,Hans-Christoph Diener,Stephen M. Davis +10 more
TL;DR: The results indicate that modern thrombectomy devices achieve faster and more complete reperfusion than do older devices, leading to improved clinical outcomes compared with intravenous alteplase alone.
324
Implementation and outcome of thrombolysis with alteplase 3–4·5 h after an acute stroke: an updated analysis from SITS-ISTR
Niaz Ahmed,Nils Wahlgren,Martin Grond,Michael G. Hennerici,Kennedy R. Lees,Robert Mikulik,Mark W Parsons,Risto O. Roine,Danilo Toni,Peter A. Ringleb +9 more
TL;DR: The implementation of the wider time window for intravenous alteplase treatment within 3-4.5 h after stroke has been implemented rapidly, with a simultaneous increase in the number of patients treated within 3 h; admission-to-treatment time has not increased.
319
Absolute risk and predictors of the growth of acute spontaneous intracerebral haemorrhage: a systematic review and meta-analysis of individual patient data
Rustam Al-Shahi Salman,Joseph Frantzias,Robert Lee,Patrick D. Lyden,Thomas W.K. Battey,Alison M. Ayres,Joshua N. Goldstein,Stephan A. Mayer,Thorsten Steiner,Xia Wang,Hisatomi Arima,Hitoshi Hasegawa,Makoto Oishi,Daniel Agustin Godoy,Luca Masotti,Dar Dowlatshahi,David Rodriguez-Luna,Carlos A. Molina,Dong-Kyu Jang,Antonio Dávalos,José Castillo,Xiaoying Yao,Jan Claassen,Bastian Volbers,Bastian Volbers,Seiji Kazui,Yasushi Okada,Shigeru Fujimoto,Kazunori Toyoda,Qi Li,Jane Khoury,Pilar Delgado,José Álvarez Sabín,Mar Hernández-Guillamon,Luis Prats-Sánchez,Chunyan Cai,Mahesh Kate,Rebecca McCourt,Chitra Venkatasubramanian,Michael N. Diringer,Yukio Ikeda,Hans Worthmann,Wendy C. Ziai,Christopher D d'Esterre,Richard I. Aviv,Peter Raab,Yasuo Murai,Allyson R. Zazulia,Kenneth Butcher,Seyed Mohammad Seyedsaadat,James C. Grotta,Joan Martí-Fàbregas,Joan Montaner,Joseph P. Broderick,Haruko Yamamoto,Dimitre Staykov,E. Sander Connolly,Magdy Selim,Rogelio Leira,B Moon,Andrew M. Demchuk,Mario Di Napoli,Yukihiko Fujii,Craig S. Anderson,Jonathan Rosand,Daniel F. Hanley,Stephen N. Davis,Barbara A. Gregson,Kennedy R. Lees,Keith W. Muir,Peng Xie,Babak Bakhshayesh,Mark McDonald,Thomas G. Brott,Paolo Pennati,Adrian R Parry-Jones,Craig J. Smith,Stephen J. Hopkins,Mark Slevin,Veronica Campi,Puneetpal Singh,Francesca Papa,Aurel Popa-Wagner,Valeria Tudorica,Ryo Takagi,Akira Teramoto,Karin Weissenborn,Heinrich Lanfermann +87 more
TL;DR: In this large patient-level meta-analysis, models using four or five predictors had acceptable to good discrimination and could inform the location and frequency of observations on patients in clinical practice, explain treatment effects in prior randomised trials, and guide the design of future trials.